Each film-coated tablet contains 5 mg, 10 mg or 20 mg tadalafil. Excipient with known effect: 115.84 mg or 463.36 mg of lactose as monohydrate.
5 mg – Treatment of erectile dysfunction in adult men.
In order for tadalafil to be effective, sexual stimulation is required.
Treatment of the symptoms of benign prostatic hyperplasia in adult men.
20 mg – Treatment of erectile dysfunction in adult men.
In order for tadalafil to be effective, sexual stimulation is required.
Treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and
III to improve exercise capacity in adults (see section 5.1).
Efficacy of the product has been shown in idiopathic PAH
(IPAH) and in PAH related to
collagen vascular disease.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of Tadalafil Hasco to patients who are using any form of organic nitrate is contraindicated (see section 4.5).
Tadalafil Hasco must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
patients with myocardial infarction within the last 90 days,
patients with unstable angina or angina occurring during sexual intercourse,
patients with New York Heart Association
Class 2 or greater heart failure in the last 6 months,
patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension,
patients with a stroke within the last 6 months.
Tadalafil Hasco is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy
(NAION), regardless of whether this episode was in connection or not with previous phosphodiesterase 5 (PDE5) inhibitor exposure (see section 4.4).
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase
stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic
hypotension (see section 4.5).
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
Each film-coated tablet contains 5 mg, 10 mg or 20 mg tadalafil. Excipient with known effect: 115.84 mg or 463.36 mg of lactose as monohydrate.
5 mg – Treatment of erectile dysfunction in adult men.
In order for tadalafil to be effective, sexual stimulation is required.
Treatment of the symptoms of benign prostatic hyperplasia in adult men.
20 mg – Treatment of erectile dysfunction in adult men.
In order for tadalafil to be effective, sexual stimulation is required.
Treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and
III to improve exercise capacity in adults (see section 5.1).
Efficacy of the product has been shown in idiopathic PAH
(IPAH) and in PAH related to
collagen vascular disease.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of Tadalafil Hasco to patients who are using any form of organic nitrate is contraindicated (see section 4.5).
Tadalafil Hasco must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
patients with myocardial infarction within the last 90 days,
patients with unstable angina or angina occurring during sexual intercourse,
patients with New York Heart Association
Class 2 or greater heart failure in the last 6 months,
patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension,
patients with a stroke within the last 6 months.
Tadalafil Hasco is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy
(NAION), regardless of whether this episode was in connection or not with previous phosphodiesterase 5 (PDE5) inhibitor exposure (see section 4.4).
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase
stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic
hypotension (see section 4.5).
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-advertisement | This cookie, set by the GDPR Cookie Consent plug-in, is used to record user consent to cookies in the "Advertising" category. | |
cookielawinfo-checkbox-analytics | A cookie used to remember the acceptance of cookies from the "Analytics" category. | |
cookielawinfo-checkbox-functional | The cookie is set by the RODO cookie consent to record the user's consent to cookies in the "Functional" category. | |
cookielawinfo-checkbox-necessary | This cookie, set by the GDPR Cookie Consent plug-in, is used to record user consent to cookies in the "Necessary" category. | |
cookielawinfo-checkbox-others | Other uncategorized cookies are those that are analyzed and have not yet been categorized. | |
cookielawinfo-checkbox-performance | This cookie is set by the GDPR Cookie Consent plugin. The cookie is used to store the user's consent to cookies in the "Performance" category. | |
CookieLawInfoConsent | Records the default button state of the corresponding category and CCPA status. It only works in coordination with the primary cookie. | |
elementor | This cookie is used by the WordPress theme of the site. It allows the site owner to implement or change the content of the site in real time. | |
viewed_cookie_policy | Records the user's consent to the use of cookies. It does not store any personal data and is recorded only on the basis of an action performed by the user (consent). |
Cookie | Duration | Description |
---|---|---|
_ga | Used to distinguish between individual users and generate statistics on how the website is used | |
_ga_* | This cookie is set by Google Analytics 4. It stores and updates a unique value for each page visited and is used to count and track page views. | |
_gat_UA-* | Google Analytics sets this cookie to track user behavior. | |
_gid | We use Google Analytics, which collects anonymous information about your visits to the site. These include such info as the sub-pages they viewed, the time they spent on the site, and the transitions between pages. |